Valley National Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Valley National Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-550	Closed	-$12K	–	1058
2026 Q1	$12K	Buy	550 +100	+22%	+$2.39K	﹤0.01%	567
2025 Q4	$12K	Hold	450	–	–	﹤0.01%	559
2025 Q3	$9K	Buy	450 +150	+50%	+$3.55K	﹤0.01%	569
2025 Q2	$6K	Buy	300 +40	+15%	+$744	﹤0.01%	629
2025 Q1	$4K	Hold	260	–	–	﹤0.01%	654
2024 Q4	$4K	Buy	+260	New	+$4.2K	﹤0.01%	634

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Valley National Advisers's ACAD Position: Q2 2026 in Review

Valley National Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 550 shares — an estimated $12K sold.

Valley National Advisers first reported a position in ACAD in Q4 2024 and held it in 6 quarters. The position peaked at $12K in Q1 2026. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Valley National Advisers reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Valley National Advisers sold 550 Acadia Pharmaceuticals shares in Q2 2026, an estimated $12K.
Valley National Advisers first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 6 quarters.
Valley National Advisers's Acadia Pharmaceuticals position peaked at $12K in Q1 2026.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.